The function of SPARC as a mediator of fibrosis

Open Rheumatology Journal

Volumn 6, Issue 1, 2012, Pages 146-155

  Trombetta eSilva, Jessica ^a,b   Bradshaw, Amy D ^b,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Collagen; Disease; Extracellular matrix; Matricellular protein

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA CATENIN; BLEOMYCIN; MEDIATOR COMPLEX; MESSENGER RNA; OSTEONECTIN; SMALL INTERFERING RNA;

DISEASE ASSOCIATION; ENZYME ACTIVITY; FIBROSIS; GENE EXPRESSION REGULATION; GLAUCOMA; HUMAN; INTESTINAL FIBROSIS; KIDNEY FIBROSIS; LIVER FIBROSIS; LUNG FIBROSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; SKIN FIBROSIS;

EID: 84863922620     PISSN: None     EISSN: 18743129     Source Type: Journal    
DOI: 10.2174/1874312901206010146     Document Type: Review

References (64)

1. Bornstein P, Sage EH. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 2002; 14(5): 608-16.
2. Sage H, Decker J, Funk S, Chow M. SPARC: a Ca2+-binding extracellular protein associated with endothelial cell injury and proliferation. J Mol Cell Cardiol 1989; 21 (Suppl 1): 13-22.
3. Wrana JL, Overall CM, Sodek J. Regulation of the expression of a secreted acidic protein rich in cysteine (SPARC) in human fibroblasts by transforming growth factor beta. Comparison of transcriptional and post-transcriptional control with fibronectin and type I collagen. Eur J Biochem 1991; 197(2): 519-28.
4. Rivera LB, Brekken RA. SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-beta1 activity. J Cell Biol 2011; 193(7): 1305-19.
5. Mendis DB, Malaval L, Brown IR. SPARC, an extracellular matrix glycoprotein containing the follistatin module, is expressed by astrocytes in synaptic enriched regions of the adult brain. Brain Res 1995; 676(1): 69-79.
6. Webersinke G, Bauer H, Amberger A, Zach O, Bauer HC. Comparison of gene expression of extracellular matrix molecules in brain microvascular endothelial cells and astrocytes. Biochem Biophys Res Commun 1992; 189(2): 877-84.
7. Yan Q, Sage EH, Hendrickson AE. SPARC is expressed by ganglion cells and astrocytes in bovine retina. J Histochem Cytochem 1998; 46(1): 3-10.
8. Holland PW, Harper SJ, McVey JH, Hogan BL. In vivo expression of mRNA for the Ca++-binding protein SPARC (osteonectin) revealed by in situ hybridization. J Cell Biol 1987; 105(1): 473-82.
9. Jundt G, Berghauser KH, Termine JD, Schulz A. Osteonectin--a differentiation marker of bone cells. Cell Tissue Res 1987; 248(2): 409-15.
10. Sangaletti S, Tripodo C, Cappetti B, et al. SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage. Am J Pathol 2011; 179(6): 3000-10.
11. Sage H, Vernon RB, Funk SE, Everitt EA, Angello J. SPARC, a secreted protein associated with cellular proliferation, inhibits cell spreading in vitro and exhibits Ca+2-dependent binding to the extracellular matrix. J Cell Biol 1989; 109(1): 341-56.
12. Schiemann BJ, Neil JR, Schiemann WP. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol Biol Cell 2003; 14(10): 3977-88.
13. Motamed K, Funk SE, Koyama H, Ross R, Raines EW, Sage EH. Inhibition of PDGF-stimulated and matrix-mediated proliferation of human vascular smooth muscle cells by SPARC is independent of changes in cell shape or cyclin-dependent kinase inhibitors. J Cell Biochem 2002; 84(4): 759-71.
14. Pichler RH, Bassuk JA, Hugo C, et al. SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-medicated mesangial cell proliferation in vitro. Am J Pathol 1996; 148(4): 1153-67.
15. Sasaki T, Hohenester E, Gohring W, Timpl R. Crystal structure and mapping by site-directed mutagenesis of the collagen-binding epitope of an activated form of BM-40/SPARC/osteonectin. EMBO J 1998; 17(6): 1625-34.
16. Carafoli F, Bihan D, Stathopoulos S, et al. Crystallographic insight into collagen recognition by discoidin domain receptor 2. Structure 2009; 17(12): 1573-81.
17. Harris BS, Zhang Y, Card L, Rivera LB, Brekken RA, Bradshaw AD. SPARC regulates collagen interaction with cardiac fibroblast cell surfaces. Am J Physiol Heart Circ Physiol 2011; 301(3): H841-7.
18. Rentz TJ, Poobalarahi F, Bornstein P, Sage EH, Bradshaw AD. SPARC regulates processing of procollagen I and collagen fibrillogenesis in dermal fibroblasts. J Biol Chem 2007; 282(30): 22062-71.
19. Francki A, Bradshaw AD, Bassuk JA, Howe CC, Couser WG, Sage EH. SPARC regulates the expression of collagen type I and transforming growth factor-beta1 in mesangial cells. J Biol Chem 1999; 274(45): 32145-52.
20. Zhou X, Tan FK, Guo X, et al. Small interfering RNA inhibition of SPARC attenuates the profibrotic effect of transforming growth factor beta1 in cultured normal human fibroblasts. Arthritis Rheum 2005; 52(1): 257-61.
21. Norose K, Clark JI, Syed NA, et al. SPARC deficiency leads to early-onset cataractogenesis. Invest Ophthalmol Vis Sci 1998; 39(13): 2674-80.
22. Bradshaw AD, Puolakkainen P, Dasgupta J, Davidson JM, Wight TN, Helene SE. SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. J Invest Dermatol 2003; 120(6): 949-55.
23. Delany AM, Amling M, Priemel M, Howe C, Baron R, Canalis E. Osteopenia and decreased bone formation in osteonectin-deficient mice. J Clin Invest 2000; 105(7): 915-23.
24. Bradshaw AD, Baicu CF, Rentz TJ, et al. Pressure overloadinduced alterations in fibrillar collagen content and myocardial diastolic function: role of secreted protein acidic and rich in cysteine (SPARC) in post-synthetic procollagen processing. Circulation 2009; 119(2): 269-80.
25. Bradshaw AD, Baicu CF, Rentz TJ, Van Laer AO, Bonnema DD, Zile MR. Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. Am J Physiol Heart Circ Physiol 2010; 298(2): H614-22.
26. Trombetta JM, Bradshaw AD. SPARC/osteonectin Functions to Maintain Homeostasis of the Collagenous Extracellular Matrix in the Periodontal Ligament. J Histochem Cytochem 2010; 58(10): 871-9.
27. McCurdy S, Baicu CF, Heymans S, Bradshaw AD. Cardiac extracellular matrix remodeling: fibrillar collagens and secreted protein acidic and rich in cysteine (SPARC). J Mol Cell Cardiol 2010; 48(3): 544-9.
28. Trombetta-eSilva J, Yu H, Arias DN, Rossa C Jr, Kirkwood KL, Bradshaw AD. LPS Induces Greater Bone and PDL Loss in SPARC-null Mice. J Dent Res 2010; 90: 477-82.
29. Chlenski A, Cohn SL. Modulation of matrix remodeling by SPARC in neoplastic progression. Semin Cell Dev Biol 2010; 21(1): 55-65.
30. Kuhn C, Mason RJ. Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis. Am J Pathol 1995; 147(6): 1759-69.
31. Chang W, Wei K, Jacobs SS, Upadhyay D, Weill D, Rosen GD. SPARC suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of beta-catenin. J Biol Chem 2010; 285(11): 8196-206.
32. Strandjord TP, Madtes DK, Weiss DJ, Sage EH. Collagen accumulation is decreased in SPARC-null mice with bleomycininduced pulmonary fibrosis. Am J Physiol 1999; 277(3 Pt 1): L628-35.
33. Savani RC, Zhou Z, Arguiri E, et al. Bleomycin-induced pulmonary injury in mice deficient in SPARC. Am J Physiol Lung Cell Mol Physiol 2000; 279(4): L743-50.
34. Wang JC, Lai S, Guo X, et al. Attenuation of fibrosis in vitro and in vivo with SPARC siRNA. Arthritis Res Ther 2010; 12(2): R60.
35. Alpers CE, Hudkins KL, Segerer S, et al. Localization of SPARC in developing, mature, and chronically injured human allograft kidneys. Kidney Int 2002; 62(6): 2073-86.
36. Kanauchi M, Nishioka M, Dohi K. Secreted protein acidic and rich in cysteine (SPARC) in patients with diabetic nephropathy and tubulointerstitial injury. Diabetologia 2000; 43(8): 1076-7.
37. Pichler RH, Hugo C, Shankland SJ, et al. SPARC is expressed in renal interstitial fibrosis and in renal vascular injury. Kidney Int 1996; 50(6): 1978-89.
38. Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME, Gilbert RE. Secreted protein acidic and rich in cysteine expression after subtotal nephrectomy and blockade of the renin-angiotensin system. J Am Soc Nephrol 1997; 8(9): 1373-82.
39. Socha MJ, Manhiani M, Said N, Imig JD, Motamed K. Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension. Am J Pathol 2007; 171(4): 1104-12.
40. Sussman AN, Sun T, Krofft RM, Durvasula RV. SPARC accelerates disease progression in experimental crescentic glomerulonephritis. Am J Pathol 2009; 174(5): 1827-36.
41. Taneda S, Pippin JW, Sage EH, et al. Amelioration of diabetic nephropathy in SPARC-null mice. J Am Soc Nephrol 2003; 14(4): 968-80.
42. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 1999; 277(1 Pt 1): C1-9.
43. Blazejewski S, Le Bail B, Boussarie L, et al. Osteonectin (SPARC) expression in human liver and in cultured human liver myofibroblasts. Am J Pathol 1997; 151(3): 651-7.
44. Frizell E, Liu SL, Abraham A, et al. Expression of SPARC in normal and fibrotic livers. Hepatology 1995; 21(3): 847-54.
45. Nakatani K, Seki S, Kawada N, et al. Expression of SPARC by activated hepatic stellate cells and its correlation with the stages of fibrogenesis in human chronic hepatitis. Virchows Arch 2002; 441(5): 466-74.
46. Camino AM, Atorrasagasti C, Maccio D, et al. Adenovirusmediated inhibition of SPARC attenuates liver fibrosis in rats. J Gene Med 2008; 10(9): 993-1004.
47. Atorrasagasti C, Aquino JB, Hofman L, et al. SPARC downregulation attenuates the profibrogenic response of hepatic stellate cells induced by TGF-beta1 and PDGF. Am J Physiol Gastrointest Liver Physiol 2011; 300(5): G739-48.
48. Girotti MR, Fernandez M, Lopez JA, et al. SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/alpha2beta1 integrin axis. J Invest Dermatol 2011; 131(12): 2438-47.
49. Kriz W, Kaissling B, Le Hir M. Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J Clin Invest 2011; 121(2): 468-74.
50. Chapman HA. Epithelial-mesenchymal interactions in pulmonary fibrosis. Annu Rev Physiol 2011; 73: 413-35.
51. Klein WP, Opitz C, Riemekasten G. Systemic sclerosis-a systematic overview: part 1-disease characteristics and classification, pathophysiologic concepts, and recommendations for diagnosis and surveillance. Vasa 2011; 40(1): 6-19.
52. Opitz C, Klein WPF, Riemekasten G. Systemic sclerosis-a systematic overview: part 2-immunosuppression, treatment of SSc-associated vasculopathy, and treatment of pulmonary arterial hypertension. Vasa 2011; 40(1): 20-30.
53. Macko RF, Gelber AC, Young BA, et al. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. J Rheumatol 2002; 29(12): 2565-70.
54. Bradshaw AD, Graves DC, Motamed K, Sage EH. SPARC-null mice exhibit increased adiposity without significant differences in overall body weight. Proc Natl Acad Sci USA 2003; 100(10): 6045-50.
55. Vuorio T, Kahari VM, Black C, Vuorio E. Expression of osteonectin, decorin, and transforming growth factor-beta 1 genes in fibroblasts cultured from patients with systemic sclerosis and morphea. J Rheumatol 1991; 18(2): 247-51.
56. Zhou X, Tan FK, Guo X, Arnett FC. Attenuation of collagen production with small interfering RNA of SPARC in cultured fibroblasts from the skin of patients with scleroderma. Arthritis Rheum 2006; 54(8): 2626-31.
57. Klopcic B, Appelbee A, Raye W, et al. Indomethacin and retinoic acid modify mouse intestinal inflammation and fibrosis: a role for SPARC. Dig Dis Sci 2008; 53(6): 1553-63.
58. Fuchshofer R, Kottler UB, Ohlmann AV, et al. SPARC is expressed in scars of the Tenon's capsule and mediates scarring properties of human Tenon's fibroblasts in vitro. Mol Vis 2011; 17: 177-85.
59. Seet LF, Su R, Toh LZ, Wong TT. In vitro analyses of the antifibrotic effect of SPARC silencing in human Tenon's fibroblasts: comparisons with mitomycin-C. J Cell Mol Med 2011; 16: 1245-59.
60. Seet LF, Su R, Barathi VA, et al. SPARC deficiency results in improved surgical survival in a novel mouse model of glaucoma filtration surgery. PLoS One 2010; 5(2): e9415.
61. Rivera LB, Bradshaw AD, Brekken RA. The regulatory function of SPARC in vascular biology. Cell Mol Life Sci 2011; 68(19): 3165-73.
62. Hohenester E, Sasaki T, Giudici C, Farndale RW, Bachinger HP. Structural basis of sequence-specific collagen recognition by SPARC. Proc Natl Acad Sci USA 2008; 105(47): 18273-7.
63. Weaver MS, Workman G, Sage EH. The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin beta1 and activation of integrin-linked kinase. J Biol Chem 2008; 283(33): 22826-37.
64. Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003; 33(3): 407-11.